Locations:
SearchReduces incidence of infection by 40% compared to standard of care
When patients receive a cardiac implantable electronic device, great care is taken to prevent infection with sterile techniques and pre-procedure intravenous antibiotics. Still, infection remains a potentially life-threatening complication in some patients.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In 2013, the FDA approved an absorbable antibacterial mesh envelope to encase implanted devices and help prevent infection. In 2019, results of an international randomized controlled trial showed that the envelope reduced incidence of infection by 40%, compared to standard-of-care infection prevention alone.
In this video, learn more about why this antibiotic envelope is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items
Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction
Next-generation mRNA vaccines are among the advancements likely to change healthcare this year
$50 million pledge will help remove sources of lead exposure from Cleveland homes
How to empower caregivers and engage patients in patient safety
Summit to cap off with Annual Top 10 Medical Innovations
The spine surgeon will oversee more than 125 staff physicians in his new role
Merlino rejoins Cleveland Clinic to help execute bold strategic vision